CLOs on the Move


 
Hitman is a Las Vegas, NV-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Dorado Marketing Inc

Dorado Marketing Inc is a Kelowna, BC-based company in the Business Services sector.

Arx Capital

Value-add and Opportunistic Real Estate Investments.

Beacon Investment Management

Beacon Investment Management is a Boston, MA-based company in the Business Services sector.

GroundsPRO

GroundsPRO, a Visterra Landscape Group partner company, specializes in turf and landscape maintenance, irrigation services, landscape design and installation, integrated pest management as well as snow and ice management services. Through ongoing employee development, focus on safety, pro-active client communication and implementing industry best practices, GroundsPRO refines our processes to continually provide unsurpassed facility services. GroundsPROs commitment to service delivery begins with our clients. Beginning each relationship by determining our clients needs and expectations, enables our team of landscape professionals to provide a customized service solution to balance the needs of the landscape as well as maximize their investment. GroundsPRO proudly services the Greater Cincinnati, Northern Kentucky, Dayton, Indianapolis and Louisville markets.

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, founded in 2006. Formerly known as Miragen Therapeutics, the company rebranded in January 2021. Viridian is dedicated to discovering, developing, and commercializing treatments for serious and rare diseases, utilizing its expertise in antibody discovery and protein engineering. The company’s product pipeline includes Veligrotug (VRDN-001), a monoclonal antibody in Phase 3 clinical trials for thyroid eye disease, and VRDN-003, a next-generation IGF-1R monoclonal antibody also in Phase 3 trials for the same condition. Additionally, Viridian is developing a portfolio of engineered anti-FcRn inhibitors, such as VRDN-006 and VRDN-008, aimed at treating various autoimmune diseases. Viridians mission is to deliver transformative therapies for patients with underserved diseases, emphasizing innovation and patient-centricity.